Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
  • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
  • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Definitions

• This invention relates to the crystalline dihydrate D of 2-methyl-4- (4-methyl-l-piperazinyl ) -10H- thieno [2, 3-b] [1, 5 Jbenzodiazepine (referred to herein as "olanzapine”) .
• the invention more specifically relates to a novel crystalline form which is particularly useful for preparing an aqueous olanzapine formulation.
• the stable crystalline Dihydrate D is particularly important for the commercial development of new formulations of the pharmaceutically active olanzapine. Olanzapine is useful for treating psychotic patients. Often an aqueous formulation or a formulation that is prepared using aqueous mixing is desired.
• Form II olanzapine is the most stable anhydrous form of olanzapine, providing a stable anhydrous formulation with pharmaceutically desired characteristics.
• a stable dihydrate was desired to provide pharmaceutically elegant aqueous formulations.
• a novel dihydrate crystal form of olanzapine has now been synthesized and characterized which possesses distinct advantages over the previously known forms, that is the material produced using the methods described in U.S. Patent No. 5,299,382 (hereinafter referred to as "the v 382 patent") , when aqueous formulations or a stable aqueous intermediate is desired.
• This novel dihydrate crystal form is clearly distinguishable therefrom by x-ray powder diffractometry.
• U.S. Patent No. 5,229,382 is hereby incorporated by reference in its entirety.
• Dihydrate D olanzapine is essential to assure a pharmaceutically elegant, aqueous formulation.
• olanzapine forms a Dihydrate B; however, this form appears to be quite unstable compared to Dihydrate D.
• Dihydrate D requires controlled conditions to prepare the substantially pure Dihydrate D material; however, once prepared, the Dihydrate D is surprisingly robust and stable. Therefore, Dihydrate D olanzapine is most desired and appears to be essential for use m preparing consistently stable commercial pharmaceutically elegant aqueous olanzapine formulations as well as for pharmaceutically elegant formulations prepared using extensive aqueous mixing.
• Dihydrate D olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following mterplanar spacmgs (d) as set forth in Table 1:
• the interplanar spacings in the column marked "d” are reported in Angstroms.
• the detector was a Kevex silicon lithium solid state detector.
• the present invention further provides an aqueous formulation comprising Dihydrate D as an active ingredient with one or more carriers or diluents therefor.
• Dihydrate B The less stable, and therefore less desired dihydrate has been designated as Dihydrate B. Applicants have discovered that a stable dihydrate is necessary for the preparation of a consistently stable pharmaceutically elegant aqueous formulation. Both dihydrate forms are clearly distinguishable from the polymorph taught in the ⁇ 82 patent.
• the polymorph obtainable by the process taught in the *382 patent is an anhydrate form which is not as stable as desired and not well suited for pharmaceutical formulations.
• the anhydrate obtainable by the process of the x 382 patent will be designated as Form I and has a typical x-ray powder diffraction pattern substantially as follows, obtained using a Siemens D5000 x-ray powder diffractometer, wherein d represents the interplanar spacing: d
• a typical example of an x-ray diffraction pattern for Form I is as follows, wherein d represents the interplanar spacing and I/I 3 represents the typical relative intensities: 9.9463 100.00 8.5579 15.18 8.2445 1.96 6.8862 14.73 6.3787 4.25 6.2439 5.21 5.5895 1.10 5.3055 0.95 4.9815 6.14 4..8333 68.37
• the interplanar spacings in the column marked “d” are in Angstroms.
• the typical relative intensities are in the column marked "I/I-'.
• a typical example of an x-ray diffraction pattern for the anhydrous Form II polymorph is as follows wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities: d ⁇ /i ⁇
• substantially pure refers to Dihydrate D associated with less than about 20° Dihydrate B, preferably less than about 5% Dihydrate B and may preferably be less than about 2 % Dihydrate B. Further, “substantially pure” Dihydrate D will contain less than about 0.5% related substances, wherein “related substances” refers to undesired chemical impurities or residual organic solvent .
• novel polymorph of the invention will be free from chemical solvates, for instance existing as the substantially pure Dihydrate D.
• Dihydrate D should contain less than about 20?, Dihydrate B, more preferably less than about 10?.
• Dihydrate B polymorph.
• Olanzapine has useful central nervous system activity. This activity has been demonstrated using well- established procedures, for example, as described in the ⁇ 382 patent.
• Dihydrate D provided by the present invention appears to have the same profile of receptor activity and has the same therapeutic uses as olanzapine described in the 382 patent. Therefore, Dihydrate D is useful for the treatment of schizophrenia, schizophreni orm disorders, psychosis, mild anxiety states, and functional bowel disorders .
• Dihydrate D is effective over a wide dosage range, the actual dose administered being dependent on the condition being treated. For example, in the treatment of adult humans, dosages of from about 0.25 to 50 mg, preferably from 1 to 30 mg, and most preferably 1 to 25 mg per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered. For treatment of central nervous system disorders, a dose range of from 1 to 30 g, preferably 2.5 to 20 mg per day is suitable .
• a typical example of an x-ray diffraction pattern for Dihydrate D is as follows, wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities :
• Dihydrate B polymorph The typical example of an x-ray diffraction pattern for the less stable Dihydrate B polymorph is as follows, wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities:
• a typical example of an x-ray diffraction pattern for the anhydrous Form II polymorph is as follows, wherein d represents the interplanar spacing and I/Ii represents the typical relative intensities:
• the term “mammal” shall refer to the Mammalia class of higher vertebrates.
• the term “mammal' includes, but is not limited to, a human.
• the term “treating” as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
• the compounds and processes of the present invention are useful for preparing compounds having beneficial central nervous system activity. Certain compounds and conditions within the scope of this invention are preferred. The following conditions, invention embodiments, and compound characteristics listed m tabular form may be independently combined to produce a variety of preferred compounds and process conditions. The following list of embodiments of this invention is not intended to limit the scope of this invention in any way. Some preferred characteristics of this invention include the following:
• Dihydrate D A tablet formulation containing substantially pure Dihydrate D which is packaged in a blister packaged under humid conditions; E) A consistently stable pharmaceutically elegant aqueous formulation containing substantially pure Dihydrate D; F) Substantially pure Dihydrate D is formulated a unit dosage form; G) Substantially pure Dihydrate D is formulated for rapid dissolution; H) Substantially pure Dihydrate D is used for treating a condition selected from the group consisting of a psychosis, schizophrenia, a schizophreniform disorder, mild anxiety, and acute mania; I) An aqueous suspension formulation containing
• Dihydrate D as an active ingredient wherein such formulation is suitable for injection.
• a tablet formulation containing substantially pure Dihydrate D which is package m an air resistant package.
• the compositions for the treatment of central nervous system conditions may be formulated as tablets, capsules, gel or suspension for transdermal delivery, suspensions or elixirs for oral use or suppositories. If such formulation is a tablet or capsule, then such formulation is most preferably packaged under humid conditions and sealed in an air impermeable sachet or blister pack.
• the compositions are formulated in a unit dosage form, each dosage containing from 0.25 to 100 mg, more usually 1 to 30 mg, of the active ingredient.
• the unit dosage form may contain from 0.25 to 200 mg of the active ingredient.
• a preferred formulation of the invention is an aqueous suspension comprising 0.25 to 75 mg or 1 to 30 mg of active ingredient together with a pharmaceutically acceptable carrier therefor.
• the starting materials for the present invention can be prepared by a variety of procedures well known to those of ordinary skill in the art.
• the material to be employed as starting materials the process of this invention can be prepared by the general procedure taught by Chakrabarti in U.S. Patent No. 5,229,382 ( ⁇ 382), herein incorporated by reference in its entirety.
• the Dihydrate D is prepared by extensive stirring of technical olanzapine, which may be prepared as described by Preparation 1, under aqueous conditions.
• aqueous conditions refers to an aqueous solvent which may be either water or a solvent mixture comprising water and an organic solvent which is sufficiently water miscible to allow the required stoichiometric quantity of water to be present the solvent mixture.
• a solvent mixture If a solvent mixture is utilized, then the organic solvent must be removed, leaving behind the water, and/or replaced with water.
• the term "extensive stirring” shall be from about one (1) hour to about six (6) days; however, the artisan will appreciate that the time will vary with the reaction conditions such as temperature, pressure, and solvent. It maybe preferred to stir for at least about four (4) hours. It is preferred that the aqueous conditions include an aqueous solvent. However, it is to be noted that to form polymorph D, rather than other dihydrate polymorphs, more extensive stirring and/or agitation is required, preferably is excess of 12 hours, more preferably in excess of 24 hours. Further, a wetting agent may be added to the aqueous mixture to speed up the formation of the stable Dihydrate D.
• Dihydrate D may be air dried or dried using other standard techniques which are sufficiently mild to avoid desolvation of the Dihydrate D.
• compositions comprising Dihydrate D, as active ingredient associated with a pharmaceutically acceptable carrier may be prepared.
• TGA thermogravimetric analysis
• DSC differential scanning calorimetery
• the active ingredient can usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
• a carrier which may be in the form of a capsule, sachet, paper or other container.
• the carrier serves as a diluent, it may be solid, semi- solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
• the active ingredient can be absorbed in a granular solid container, for example, in a sachet.
• compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
• quick release formulation s described in US. Patent Nos. 4,305,502 and 4,371,516, hereby incorporated by reference.
• such formulation includes a pharmaceutically acceptable flavoring agent or combinations of such agents, including natural and synthetic flavoring agents such as ASPARTANE® and flavor enhancing agents, such as the commercial product VELTOL® (Pfizer) ; preservatives such as methyl paraben, propyl paraben and combinations thereof are further preferred.
• a pharmaceutically acceptable flavoring agent or combinations of such agents including natural and synthetic flavoring agents such as ASPARTANE® and flavor enhancing agents, such as the commercial product VELTOL® (Pfizer) ; preservatives such as methyl paraben, propyl paraben and combinations thereof are further preferred.
• a particularly preferred method for treating a sub ect suffering from or susceptible to a psychotic condition comprises administering an aqueous oral suspension formulation comprising Dihydrate D olanzapine and pharmaceutically acceptable carriers and/or excipients .
• aqueous oral suspension formulation comprising Dihydrate D olanzapine and pharmaceutically acceptable carriers and/or excipients .
• a sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction.
• the reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by
• a sample of gelatin powder (1 g) is admixed with maltodextran (2 g) , gelatin A (0.5 g) ; sucrose (2 g) and ASPARTANE® (1 g) .
• Distilled water is added to the mixture to about 100 L total volume.
• the mixture is stirred and heated to about 60°C.
• the mixture should be heated until it appears to be a clear solution.
• the mixture is cooled to about 37°C.
• Blister molds are prepared by rinsing with a solution of lecithein (about 10%) in about 190 proof grain alcohol. The molds so prepared are dried at room temperature. An aliquot of the cooled mixture is added to each compartment of the mold.
• the mold containing the mixture is cooled to a temperature of about -10°C or lower for about 40 minutes.
• the mold containing the mixture is removed from the ⁇ -10°C environment and about 20 mg of anhydrous olanzapine is added to the surface of each tablet within the mold.
• the mold should remain protected from thawing.
• the mold containing the mixture and olanzapine is again cooled to about -10°C for about 40 minutes.
• the mold is removed from the cooled about -10°C environment and an additional aliquot of the gelatin based mixture (to which no olanzapine has been added) is added to the surface of each compartment of the mold prepared as described supra .
• the mold is again cooled to about -10°C for about 40 minutes.
• the tablets are removed from the mold to a mesh plastic bag.
• the bag and its contents are hermetically sealed in a container of anhydrous ethyl alcohol and maintained at a temperature of -20°C.
• the tablets are maintained in the hermetically sealed bag until the tablets are completely dehydrated. The dehydration continues until no odor or other evidence of alcohol can be detected on the tablets.
• the formulation is studied using x-ray powder diffraction techniques to assure that substantially pure Dihydrate D is present.
• the medicament is passed through a No . 45 mesh U.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste.
• the benzoic acid solution, flavor and color is diluted with some of the water and added to the paste with stirring. Sufficient water is then added to produce the required volume.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=21832112

Family Applications (1)

Country Status (35)

Cited By (49)

Families Citing this family (19)

Citations (2)

Family Cites Families (7)

• 1997
  • 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
  • 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
  • 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
  • 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
  • 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active IP Right Cessation
  • 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
  • 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
  • 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
  • 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
  • 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
  • 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
  • 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
  • 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
  • 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
  • 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
  • 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
  • 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Application Discontinuation
  • 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
  • 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
  • 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
  • 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
  • 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
  • 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
  • 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
  • 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
  • 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
  • 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
  • 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
  • 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
  • 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
  • 1997-09-23 EG EG98597A patent/EG23815A/xx active
  • 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
• 1998
  • 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
  • 1998-09-21 HK HK98110803A patent/HK1009809A1/xx not_active IP Right Cessation
• 1999
  • 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events